𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Clinical significance of serum bilirubin levels under ursodeoxycholic acid therapy in patients with primary biliary cirrhosis

✍ Scribed by Anne-Marie Bonnand; E. Jenny Heathcote; Keith D. Lindor; Renée Eugénie Poupon

Publisher
John Wiley and Sons
Year
1999
Tongue
English
Weight
82 KB
Volume
29
Category
Article
ISSN
0270-9139

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Effect of pretransplantation ursodeoxych
Effect of pretransplantation ursodeoxycholic acid therapy on the outcome of liver transplantation in patients with primary biliary cirrhosis
✍ Heathcote, E. Jenny ;Stone, Julie ;Cauch-Dudek, Karen ;Poupon, Raoul ;Chazouille 📂 Article 📅 1999 🏛 Wiley (John Wiley & Sons) 🌐 English ⚖ 42 KB 👁 1 views

As ursodeoxycholic acid (UDCA) delays the need for transplantation, this could result in patients with more comorbid disease, therefore more likely to have a worse outcome posttransplantation. The aim of this study is to compare posttransplantation outcome in patients who received UDCA versus placeb

Oral budesonide in the treatment of pati
Oral budesonide in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid
✍ Paul Angulo; Roberta A. Jorgensen; Jill C. Keach; E. Rolland Dickson; Coleman Sm 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 236 KB 👁 1 views

Ursodeoxycholic acid (UDCA) is a safe and effective medical therapy for most patients with primary biliary cirrhosis (PBC). However, some patients show an incomplete response to UDCA therapy. Treatment with corticosteroids may be of benefit although at the expense of systemic side effects. Budesonid

Does antimitochondrial antibody status a
Does antimitochondrial antibody status affect response to treatment in patients with primary biliary cirrhosis? Outcomes of ursodeoxycholic acid therapy and liver transplantation
✍ W R Kim; J J Poterucha; R A Jorgensen; K P Batts; H A Homburger; E R Dickson; R 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 270 KB 👁 2 views

rum. 1 In the past decade, two treatment modalities have Approximately 5% to 10% of patients with features otherbeen shown to be effective in the treatment for PBC, dewise consistent with primary biliary cirrhosis (PBC) lack antipending on the stage of the disease. For patients with less mitochondri

Differences in the metabolism and dispos
Differences in the metabolism and disposition of ursodeoxycholic acid and of its taurine-conjugated species in patients with primary biliary cirrhosis
✍ Pietro Invernizzi; Kenneth D. Setchell; Andrea Crosignani; Pier Maria Battezzati 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 180 KB 👁 2 views

The clinical effectiveness of ursodeoxycholate in the treatment of liver disease may be limited by its poor absorption and extensive biotransformation. Because in vitro and in vivo studies suggest that the more hydrophilic bile acid tauroursodeoxycholate has greater beneficial effects than ursodeoxy